Wall Street Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

Wall Street Associates’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-2,505	Closed	-$327K	–	219
2016 Q1	$327K	Hold	2,505	–	–	0.14%	171
2015 Q4	$352K	Hold	2,505	–	–	0.1%	254
2015 Q3	$333K	Buy	2,505 +438	+21%	+$75.4K	0.06%	278
2015 Q2	$364K	Hold	2,067	–	–	0.03%	301
2015 Q1	$357K	Buy	2,067 +450	+28%	+$77.2K	0.03%	292
2014 Q4	$265K	Sell	1,617 -788	-33%	-$131K	0.03%	305
2014 Q3	$386K	Buy	+2,405	New	+$370K	0.04%	271

Other funds holding JAZZ

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wall Street Associates's JAZZ Position: Q2 2016 in Review

Wall Street Associates sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2016, closing a stake of 2,505 shares — an estimated $327K sold.

Wall Street Associates first reported a position in JAZZ in Q3 2014 and held it in 7 quarters. The position peaked at $386K in Q3 2014. 366 funds tracked by Wall St. Rank hold JAZZ as of Q2 2016.

Wall Street Associates reported no remaining Jazz Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Wall Street Associates sold 2,505 Jazz Pharmaceuticals shares in Q2 2016, an estimated $327K.
Wall Street Associates first reported a position in Jazz Pharmaceuticals in Q3 2014 and held it in 7 quarters.
Wall Street Associates's Jazz Pharmaceuticals position peaked at $386K in Q3 2014.
366 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2016.

Based on Wall Street Associates's 13F filing for Q2 2016, filed 12 Aug 2016.